Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Garrett W Rhyasen

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Blood|April 30, 2014
OKT3 prevents xenogeneic GVHD and allows reliable xenograft initiation from unfractionated human hematopoietic tissuesMark Wunderlich, Ryan A Brooks, Rushi Panchal, et al.
Frontiers in Immunology|November 23, 2020
TNFAIP3 Plays a Role in Aging of the Hematopoietic SystemMolly A Smith, Ashley E Culver-Cochran, Emmalee R Adelman, et al.
Plos One|July 24, 2018
BRD4 amplification facilitates an oncogenic gene expression program in high-grade serous ovarian cancer and confers sensitivity to BET inhibitorsGarrett W Rhyasen, Yi Yao, Jingwen Zhang, et al.
Blood|October 24, 2014
Modeling de novo leukemogenesis from human cord blood with MN1 and NUP98HOXD13Suzan Imren, Michael Heuser, Maura Gasparetto, et al.
Cancer Cell|July 13, 2013
Targeting IRAK1 as a therapeutic approach for myelodysplastic syndromeGarrett W Rhyasen, Lyndsey Bolanos, Jing Fang, et al.
Molecular Cancer Therapeutics|August 31, 2016
AZD5153: A Novel Bivalent BET Bromodomain Inhibitor Highly Active against Hematologic MalignanciesGarrett W Rhyasen, Maureen M Hattersley, Yi Yao, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Blood|April 30, 2014
OKT3 prevents xenogeneic GVHD and allows reliable xenograft initiation from unfractionated human hematopoietic tissuesMark Wunderlich, Ryan A Brooks, Rushi Panchal, et al.
Frontiers in Immunology|November 23, 2020
TNFAIP3 Plays a Role in Aging of the Hematopoietic SystemMolly A Smith, Ashley E Culver-Cochran, Emmalee R Adelman, et al.
Plos One|July 24, 2018
BRD4 amplification facilitates an oncogenic gene expression program in high-grade serous ovarian cancer and confers sensitivity to BET inhibitorsGarrett W Rhyasen, Yi Yao, Jingwen Zhang, et al.
Blood|October 24, 2014
Modeling de novo leukemogenesis from human cord blood with MN1 and NUP98HOXD13Suzan Imren, Michael Heuser, Maura Gasparetto, et al.
Cancer Cell|July 13, 2013
Targeting IRAK1 as a therapeutic approach for myelodysplastic syndromeGarrett W Rhyasen, Lyndsey Bolanos, Jing Fang, et al.
Molecular Cancer Therapeutics|August 31, 2016
AZD5153: A Novel Bivalent BET Bromodomain Inhibitor Highly Active against Hematologic MalignanciesGarrett W Rhyasen, Maureen M Hattersley, Yi Yao, et al.
Pageof 1